Biosimilars | Specialty

Dr. Welslau on the Rationale for Rituximab Biosimilar Combination in DLBCL

June 29th 2020

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Bevacizumab Biosimilar Aybintio Receives Positive European Opinion

June 26th 2020

The Committee for Medicinal Products for Human Use has recommended approval of Aybintio, a bevacizumab (Avastin) biosimilar for the treatment of patients with the same types of cancer for which the reference product is indicated in the European Union.

Dr. Ramakrishnan on the Promise of Biosimilars in Hematology

June 22nd 2020

Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.

FDA Approves Pfizer’s Pegfilgrastim Biosimilar

June 11th 2020

The FDA has approved pegfilgrastim-apgf, a biosimilar to pegfilgrastim, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Dr. Cuellar on the Pharmacoeconomic Benefits of Biosimilars

April 30th 2020

Sandra Cuellar, PharmD, BCOP, discusses the pharmacoeconomic benefits of biosimilars.

Trastuzumab Biosimilar Ontruzant Enters US Oncology Market

April 15th 2020

Trastuzumab-dttb (Ontruzant) is now officially available for clinical use in the United States.

Emergence of Biosimilars in Oncology

March 16th 2020

FDA Reviewing Bevacizumab Biosimilar

March 6th 2020

The FDA has accepted a biologics license application for a proposed biosimilar for bevacizumab.

O'Regan Shares Insight on Biosimilar Revolution in Oncology

February 19th 2020

Ruth O’Regan, MD, shares her perspective on the use of biosimilars in breast cancer and their future in oncology.

Schwartzberg Sheds Light on Rise of Biosimilars in Oncology

February 6th 2020

Lee Schwartzberg, MD, FACP, advocates for the increased use of biosimilars in oncology and discusses the benefits of these agents for patients and providers.